{"filing":{"accession_number":"0001104659-26-081562","cik":"0001567892","ticker":null,"company_name":"Keenova Therapeutics plc","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"tm2619951d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465926081562/tm2619951d1_8k.htm"},"events":[{"id":16597,"run_id":14829,"accession_number":"0001104659-26-081562","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Keenova announced positive Phase 3 clinical trial results for XIAFLEX in treating plantar fibromatosis, meeting its primary endpoint of pain reduction and key secondary endpoints of functional improvement. The company plans to submit an FDA application in Q4 2026 with an expected launch in 2028 for a market of approximately 300,000 patients.","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14748,"accession_number":"0001104659-26-081562","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Keenova announced positive Phase 3 clinical trial results for XIAFLEX in treating plantar fibromatosis, with plans to submit an FDA application in Q4 2026. This is a material operational/clinical milestone for a therapeutics company—the successful completion of a pivotal Phase 3 trial and regulatory pathway advancement—but does not fit the specific earnings_release category (which typically applies to financial results disclosures) or any other named event type. The disclosure is clearly material to investors assessing the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:18:41.266610+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14749,"accession_number":"0001104659-26-081562","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Keenova disclosed positive Phase 3 clinical trial results for XIAFLEX in treating plantar fibromatosis, meeting its primary endpoint (pain reduction) and key secondary endpoints (functional improvement). The company plans to submit an FDA application in Q4 2026 and expects launch in 2028 for a market of approximately 300,000 patients. This is a material operational/clinical milestone for a therapeutic company, representing significant progress toward a new indication for an existing drug, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:18:41.266610+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14748,"accession_number":"0001104659-26-081562","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Keenova announced positive Phase 3 clinical trial results for XIAFLEX in treating plantar fibromatosis, with plans to submit an FDA application in Q4 2026. This is a material operational/clinical milestone for a therapeutics company—the successful completion of a pivotal Phase 3 trial and regulatory pathway advancement—but does not fit the specific earnings_release category (which typically applies to financial results disclosures) or any other named event type. The disclosure is clearly material to investors assessing the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:18:41.266610+00:00","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-07-08"},{"id":14749,"accession_number":"0001104659-26-081562","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Keenova disclosed positive Phase 3 clinical trial results for XIAFLEX in treating plantar fibromatosis, meeting its primary endpoint (pain reduction) and key secondary endpoints (functional improvement). The company plans to submit an FDA application in Q4 2026 and expects launch in 2028 for a market of approximately 300,000 patients. This is a material operational/clinical milestone for a therapeutic company, representing significant progress toward a new indication for an existing drug, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:18:41.266610+00:00","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-07-08"}]}